Trials / Completed
CompletedNCT07398586
The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative Colitis
The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative Colitis as Well as the Response to Vedolizumab
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 898 (actual)
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
From January 2020 to December 2024, diagnosed ulcerative colitis(UC) patients and gender- and age-matched normal controls were enrolled from the Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Investigators' aim is to investigate the associations of IL-7R gene polymorphisms with the risk and clinicopathological characteristics of UC, and to analyze the effects of IL-7R gene variations on the clinical response of vedolizumab(VDZ) treatment in UC patients.
Detailed description
From January 2020 to December 2024, diagnosed UC patients and gender- and age-matched normal controls were enrolled from the Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Genotypes of IL-7R were determined by multiplex polymerase chain reaction-ligase detection reaction technique. Chi-square test and unconditional logistic regression model were used to analyze the difference in distribution of IL-7R gene polymorphisms between UC group and normal control group, as well as the effects of IL-7R gene variations on the clinicopathological characteristics and 14-week clinical response to VDZ treatment of participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Vedolizumab | Intravenous injection of VDZ (300mg/time) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of VDZ every 8 weeks to maintain treatment. |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2026-02-10
- Last updated
- 2026-02-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07398586. Inclusion in this directory is not an endorsement.